Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and development of immunotherapies for cancers, inflammatory and infectious diseases based on its patented PD-1-enhanced DNA vaccine andAnti-Δ42PD1 Antibody Immune Blockage Platforms.
Location: China, Hong Kong, Sha Tin District
Employees: 11-50
Founded date: 2015
Investors 1
| Date | Name | Website |
| - | Gobi Partn... | gobi.vc |
Mentions in press and media 6
| Date | Title | Description | Source |
| 04.08.2023 | Gobi Partners’ strategic health tech investments signal grow... | To solidify its position in the health tech sector, pan-Asian venture capital firm Gobi Partners has... | kr-asia.co... |
| 27.07.2023 | Immuno Cure Completed US$12M First Close of Series A Financi... | Advancing DNA vaccines & Immunotherapies for HIV, Cancers & Infectious Diseases HONG KONG S... | africanews... |
| 16.02.2023 | Immuno Cure kick off Phase I Clinical Trial in Shenzhen | A significant step for developing our PD-1-Enhanced DNA Vaccine against HIV/AIDS HONG KONG, Feb. 16... | en.prnasia... |
| 01.11.2022 | Immuno Cure appoints new CFO | Strengthening of executive management team to propel growth strategy HONG KONG, Nov. 1, 2022 /PRNew... | en.prnasia... |
| 17.10.2022 | Immuno Cure secured maximum subsidy from HKSTP | Significant funding support for HIV Vaccine Clinical Trial HONG KONG SAR – Media OutReach – 17 Octo... | africanews... |
| - | Immuno Cure | “Immuno Cure is a biotechnology group based in the Hong Kong Science Park, focusing on research and ... | fastfounde... |